Fig. 5: FASN suppressed cell apoptosis via ERK1/2/Bcl-xL in suspended cells.
From: Anoikis resistant mediated by FASN promoted growth and metastasis of osteosarcoma
a Expression of FASN, p-ERK1/2 and Bcl-xL in stable cell lines silencing FASN. Expression of FASN, p-ERK1/2, and Bcl-xL in stable cell lines overexpressing FASN. b Expression of p-ERK1/2 and Bcl-xL after the stable cell lines overexpressing FASN were treated with ERK1/2 inhibitor GDC-0973. c Apoptotic indexes of cells treated with GDC-0973 (10 μM) were detected by Annexin V double staining. The apoptotic cells (Q3 and Q2) were more in the GDC-0973 treated FASN overexpression hFOB 1.19 and Saos-2 cells. The apoptotic cells (Q3 and Q2) were less in the GDC-0973 treated FASN overexpression hFOB 1.19 and Saos-2 cells compared with their controls. d Quantitation of apoptotic hFOB 1.19 and Saos-2 cells. e Expression of FASN, p-ERK1/2 and Bcl-xL in four kinds of osteosarcoma cells. f (Left) Relative expression levels of FASN in 143B and 143B-AR cells; (Right) Relative expression levels of FASN, p-ERK1/2 and Bcl-xL in 143B-AR cells. g Flow chart of summary of the relationships of FASN, p-ERK1/2, and Bcl-xL
